Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIBLGH)

• Drug Name: Cyanopindolol Drug Info
• Synonyms: Cyanopindolol; 69906-85-0; CYANOPINDOLOL HEMIFUMARATE; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile; (+-)-Cyanopindolol; (-)-Cyanopindolol; AC1L4E3D; CYANOPINDOLOL(+/-); GTPL132; SCHEMBL353756; CHEMBL378501; CTK8E9328; BDBM81499; CHEBI:125406; PDSP1_001601; PDSP2_001585; PDSP1_001094; PDSP2_001078; NSC707473; CAS_155346; NSC_155346; NSC-707473; 1H-Indole-2-carbonitrile, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-; NCI60_038172; RT-012114; SR-01000597973; L000210; SR-01000597973-1; BRD-A47884604-001-01-7

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 155346
  ChEBI ID: CHEBI:125406
  CAS Number: CAS 69906-85-0
  TTD Drug ID: DMIBLGH

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1 receptor (5HT1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aryl piperazine derivative 16	DM63XHT	N. A.	N. A.	Patented	[5]
Aryl piperazine derivative 14	DMY8NEL	N. A.	N. A.	Patented	[5]
Aryl piperazine derivative 15	DMRK4IE	N. A.	N. A.	Patented	[5]
RU 24969	DMVW3I9	N. A.	N. A.	Terminated	[6]
Befiperide	DMGAPH1	Anxiety disorder	6B00-6B0Z	Terminated	[7]
FCE-25876	DMR3ZWA	Major depressive disorder	6A70.3	Terminated	[8]
SRSS-023	DMUGPDB	Migraine	8A80	Terminated	[9]

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[10]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[11]
Terbutaline	DMD4381	Asthma	CA23	Approved	[12]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[13]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[14]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[18]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[19]

Drug(s) Affected By Beta-1 adrenergic receptor (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[20]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[21]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[25]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[26]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]

Drug(s) Affected By Beta-3 adrenergic receptor (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[29]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Phenylephrine	DMZHUO5	Allergic rhinitis	CA08.0	Approved	[32]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[33]
[3H]CGP12177	DMZN1A3	Discovery agent	N.A.	Investigative	[34]
KOJIC ACID	DMP84CS	Discovery agent	N.A.	Investigative	[35]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1 receptor (5HT1R)	TTWT5K7	NOUNIPROTAC	Antagonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Beta-1 adrenergic receptor (ADRB1)	OTQBWN4U	ADRB1_HUMAN	Protein Interaction/Cellular Processes	[3]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Protein Interaction/Cellular Processes	[3]
Beta-3 adrenergic receptor (ADRB3)	OTPMG4V7	ADRB3_HUMAN	Protein Interaction/Cellular Processes	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 132).
• [2] The inhibitory effect of serotonin on the spontaneous discharge of suprachiasmatic neurons in hypothalamic slice is mediated by 5-HT(7) receptor. Brain Res Bull. 2001 Mar 1;54(4):395-8.
• [3] Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003 Jan 26;460(1):19-26. doi: 10.1016/s0014-2999(02)02875-3.
• [4] Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):310-21. doi: 10.1007/pl00005357.
• [5] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [6] Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br J Pharmacol. 1986 Oct;89(2):377-84.
• [7] Behavioral Pharmacology of 5-ht. Paul Bevan, Paul Bevan Duphar, Alexander R. Cools. 2013. Figure(15.2).
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001389)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089)
• [10] Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
• [11] Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
• [12] Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
• [13] beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
• [14] Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
• [15] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [16] Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
• [17] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [18] Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
• [19] Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
• [20] The Arg389Gly 1-adrenoceptor gene polymorphism influences the acute effects of -adrenoceptor blockade on contractility in the human heart. Clin Res Cardiol. 2011 Aug;100(8):641-7. doi: 10.1007/s00392-011-0288-1. Epub 2011 Feb 11.
• [21] Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol. 2003 Jun;63(6):1312-21. doi: 10.1124/mol.63.6.1312.
• [22] Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.
• [23] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [24] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [25] Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism. Am J Cardiol. 1989 Jun 5;63(19):3I-6I. doi: 10.1016/0002-9149(89)90120-3.
• [26] Effects of chronic amiodarone treatment on human myocardial beta adrenoceptor density and adenylate cyclase response. Cardiovasc Res. 1991 Jun;25(6):503-9. doi: 10.1093/cvr/25.6.503.
• [27] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [28] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [29] Impact of rosiglitazone on the expression of beta3-AR in the stable cell lines expressed beta3-AR gene. Clin Chem Lab Med. 2007;45(11):1511-6. doi: 10.1515/CCLM.2007.315.
• [30] Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II. J Med Chem. 2008 Jul 10;51(13):4002-20. doi: 10.1021/jm8000345. Epub 2008 Jun 14.
• [31] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [32] Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol. 2005 Jul 19;46(2):351-9. doi: 10.1016/j.jacc.2005.03.061.
• [33] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [34] Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human -adrenoceptors. J Med Chem. 2011 Oct 13;54(19):6874-87. doi: 10.1021/jm2008562. Epub 2011 Sep 16.
• [35] Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
• [36] Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. doi: 10.1007/s00210-003-0860-y. Epub 2004 Jan 17.